NASDAQ:CYTK - Cytokinetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.31
  • Forecasted Upside: 45.69 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
▼ -3.5 (-8.30%)

This chart shows the closing price for CYTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytokinetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

Analyst Price Target is $56.31
▲ +45.69% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $56.31, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 45.69% upside from the last price of $38.65.

This chart shows the closing price for CYTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Cytokinetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022MizuhoLower Price TargetNA$80.00 ➝ $54.00Medium
5/5/2022Needham & Company LLCBoost Price Target$52.00 ➝ $60.00High
4/29/2022HC WainwrightBoost Price Target$69.00 ➝ $75.00High
2/17/2022Cantor FitzgeraldLower Price Target$57.00 ➝ $53.00High
1/28/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00High
12/21/2021OppenheimerInitiated CoverageOutperform$55.00High
12/21/2021HC WainwrightBoost Price TargetBuy$62.00 ➝ $69.00High
12/10/2021JPMorgan Chase & Co.Initiated CoverageOverweight$58.00Medium
12/1/2021MizuhoBoost Price TargetBuy$45.00 ➝ $54.00High
11/4/2021HC WainwrightBoost Price TargetPositive ➝ Buy$58.00 ➝ $62.00High
11/4/2021JMP SecuritiesReiterated RatingBuyHigh
10/12/2021Cantor FitzgeraldBoost Price TargetOverweight$48.00 ➝ $57.00Low
10/8/2021HC WainwrightReiterated RatingBuy$58.00Medium
10/8/2021Morgan StanleyBoost Price TargetOverweight$38.00 ➝ $45.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$75.00High
9/7/2021BarclaysBoost Price TargetOverweight$40.00 ➝ $45.00High
8/9/2021Piper SandlerLower Price TargetOverweight$42.00 ➝ $40.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$53.00 ➝ $58.00High
7/20/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$35.00 ➝ $48.00High
7/20/2021BarclaysBoost Price TargetOverweight$28.00 ➝ $40.00High
7/19/2021JMP SecuritiesBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $44.00High
7/19/2021Raymond JamesBoost Price TargetOutperform$37.00 ➝ $54.00High
7/19/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$25.00 ➝ $42.00High
7/19/2021HC WainwrightBoost Price TargetBuy$41.00 ➝ $53.00High
7/19/2021Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $48.00High
7/1/2021MizuhoInitiated CoverageBuy$36.00Low
5/11/2021MizuhoBoost Price TargetBuy$26.00 ➝ $36.00Medium
4/19/2021Morgan StanleyBoost Price TargetOverweight$24.00 ➝ $35.00Low
3/11/2021Wolfe ResearchInitiated CoverageOutperform$50.00High
2/18/2021BarclaysInitiated CoverageOverweight$28.00High
1/20/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $41.00High
12/16/2020Morgan StanleyBoost Price TargetOverweight$22.00 ➝ $24.00Low
12/14/2020MizuhoLower Price TargetBuy$31.00 ➝ $26.00High
11/24/2020Raymond JamesReiterated RatingBuyHigh
11/23/2020HC WainwrightLower Price TargetBuy$43.00 ➝ $22.00High
11/16/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
11/16/2020Morgan StanleyLower Price TargetOverweight$24.00 ➝ $22.00High
10/28/2020The Goldman Sachs GroupInitiated CoverageNeutral$16.00Low
10/12/2020Morgan StanleyLower Price TargetOverweight$35.00 ➝ $24.00Low
10/8/2020HC WainwrightLower Price TargetPositive ➝ Buy$59.00 ➝ $43.00High
10/6/2020Cantor FitzgeraldBoost Price TargetOverweight$41.00 ➝ $48.00Medium
7/23/2020Piper SandlerBoost Price TargetOverweight$33.00 ➝ $36.00Low
7/23/2020HC WainwrightBoost Price TargetBuy$38.00 ➝ $59.00Low
7/15/2020Cantor FitzgeraldBoost Price TargetOverweight$29.00 ➝ $41.00High
7/15/2020JMP SecuritiesBoost Price TargetOutperform$23.00 ➝ $29.00High
7/14/2020Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $45.00High
7/14/2020Piper SandlerBoost Price Target$28.00 ➝ $33.00High
7/14/2020HC WainwrightBoost Price TargetBuy$35.00 ➝ $38.00High
7/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00High
7/7/2020Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $35.00High
5/23/2020MizuhoInitiated CoverageBuy$31.00Low
5/12/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $29.00Low
5/11/2020HC WainwrightBoost Price TargetPositive ➝ Buy$30.00 ➝ $35.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$24.00Low
5/4/2020MizuhoInitiated CoverageBuy$31.00High
4/27/2020Morgan StanleyReiterated RatingBuy$25.00Low
4/24/2020HC WainwrightReiterated RatingBuyMedium
4/19/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
4/17/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $23.00High
4/14/2020HC WainwrightReiterated RatingBuy$30.00Medium
4/14/2020Needham & Company LLCReiterated RatingBuy$24.00Low
4/9/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$14.00 ➝ $25.00High
3/31/2020HC WainwrightReiterated RatingBuy$30.00High
3/4/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
2/26/2020HC WainwrightReiterated RatingBuy$30.00Low
2/7/2020HC WainwrightReiterated RatingBuyHigh
11/1/2019Needham & Company LLCReiterated RatingBuy$24.00High
10/4/2019Needham & Company LLCReiterated RatingBuy$16.00Low
10/4/2019HC WainwrightReiterated RatingBuy$26.00Medium
9/16/2019Piper Jaffray CompaniesReiterated RatingOverweight$14.00 ➝ $20.00High
9/13/2019JMP SecuritiesSet Price TargetBuy$23.00Medium
9/6/2019Cantor FitzgeraldReiterated RatingOverweight$14.00 ➝ $20.00Medium
8/9/2019Needham & Company LLCSet Price TargetBuy$16.00Medium
8/9/2019Morgan StanleySet Price TargetHold$16.00Medium
7/15/2019Morgan StanleySet Price TargetHold$11.00High
7/15/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00High
5/10/2019Cantor FitzgeraldReiterated RatingBuy$14.00Medium
5/6/2019HC WainwrightBoost Price TargetBuy$21.00 ➝ $26.00Medium
4/23/2019HC WainwrightSet Price TargetBuy$21.00High
3/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$12.00 ➝ $13.00High
3/19/2019HC WainwrightReiterated RatingBuy$21.00High
1/22/2019HC WainwrightReiterated RatingBuy$21.00Medium
12/5/2018HC WainwrightSet Price TargetBuy$21.00Low
12/5/2018Cantor FitzgeraldReiterated RatingBuy$14.00Low
11/27/2018HC WainwrightReiterated RatingBuy$21.00Low
11/2/2018HC WainwrightSet Price TargetBuy$21.00High
11/2/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
10/17/2018HC WainwrightSet Price TargetBuy$21.00High
10/17/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
10/5/2018HC WainwrightLower Price TargetBuy ➝ Buy$24.00 ➝ $21.00Low
10/5/2018Morgan StanleySet Price TargetHold$10.00High
10/3/2018Cantor FitzgeraldReiterated RatingBuy$14.00High
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$14.00High
9/10/2018Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$10.00Medium
8/1/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$18.00 ➝ $9.00High
7/27/2018HC WainwrightSet Price TargetBuy$24.00High
6/18/2018HC WainwrightBoost Price TargetBuy$24.00High
6/18/2018Piper Jaffray CompaniesLower Price TargetOverweight$13.00High
6/17/2018Cantor FitzgeraldReiterated RatingHold$10.00High
4/27/2018HC WainwrightReiterated RatingBuy$20.00High
4/24/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $18.00High
2/20/2018CowenReiterated RatingBuy$11.00Medium
2/12/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
1/19/2018HC WainwrightSet Price TargetBuy$20.00High
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00Low
11/29/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00Low
11/22/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$25.00 ➝ $17.00N/A
11/22/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$21.00 ➝ $10.00N/A
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 ➝ $13.00N/A
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/A
11/21/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00N/A
11/21/2017HC WainwrightLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00N/A
10/29/2017Needham & Company LLCReiterated RatingBuy$22.00N/A
10/27/2017HC WainwrightReiterated RatingBuy$26.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$24.00 ➝ $25.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$21.00Medium
9/20/2017HC WainwrightReiterated RatingBuy$26.00Low
9/18/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
9/17/2017Needham & Company LLCReiterated RatingBuy$22.00Low
8/4/2017CowenReiterated RatingBuy$19.00Low
8/3/2017HC WainwrightSet Price TargetBuy$26.00High
7/31/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$24.00High
5/19/2017Cantor FitzgeraldReiterated RatingOverweightMedium
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 5 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $38.65
Low: $38.45
High: $42.16

50 Day Range

MA: $38.25
Low: $33.93
High: $43.40

52 Week Range

Now: $38.65
Low: $17.72
High: $47.90


1,189,106 shs

Average Volume

980,928 shs

Market Capitalization

$3.31 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: Barclays PLC, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James,, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for CYTK.

What is the current price target for Cytokinetics?

0 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $56.31, suggesting a possible upside of 45.7%.
View the latest price targets for CYTK.

What is the current consensus analyst rating for Cytokinetics?

Cytokinetics currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYTK will outperform the market and that investors should add to their positions of Cytokinetics.
View the latest ratings for CYTK.

How do I contact Cytokinetics' investor relations team?

Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected] The official website for Cytokinetics is Learn More about contacing Cytokinetics investor relations.